Lumosa Therapeutics Co., Ltd.
Taipei Exchange 6535.TWO
Lumosa Therapeutics Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 29.71
Lumosa Therapeutics Co., Ltd. Price to Book Ratio (P/B) is 29.71 on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
-
Lumosa Therapeutics Co., Ltd. 52-week high Price to Book Ratio (P/B) is 43.49 on October 28, 2024, which is 46.38% above the current Price to Book Ratio (P/B).
-
Lumosa Therapeutics Co., Ltd. 52-week low Price to Book Ratio (P/B) is 19.44 on December 16, 2024, which is -34.55% below the current Price to Book Ratio (P/B).
-
Lumosa Therapeutics Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 30.99.
Key data
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
Market news
Loading...
Taipei Exchange: 6535.TWO
| CEO | Li Fang Pan |
| IPO Date | July 16, 2015 |
| Location | |
| Headquarters | No. 3-2, Park Street |
| Employees | 47 |
| Sector | Health Care |
| Industries | |
Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email